Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan

PloS One
Jason C HsuPeng-Chan Lin

Abstract

Since 2012, several immune checkpoint inhibitors have been approved by the Taiwan FDA for various types of cancer treatment. However, none of them are covered by Taiwan National Health Insurance due to the fact that they are expensive, and there is a lack of clinical evidence as to their effectiveness. This study was aimed toward an exploration of clinical experiences with use of immune checkpoint inhibitors, including indications, prescription types, drug effectiveness, adverse drug event types, and incidence, all of which shall serve as references for future clinical drug use. This is a retrospective study focusing on three immune checkpoint inhibitors (ipilimumab, nivolumab, and pembrolizumab), which are available for cancer treatment in Taiwan. We collected data from medical records for the period from January 1st, 2015 to January 12th, 2017 at National Cheng Kung University Hospital (NCKUH), a medical center in southern Taiwan, and recorded these cases until May 31st, 2017. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method, and adverse drug reaction odds ratios were analyzed using a chi-square analysis. The 50 patients under consideration in this study had used any one o...Continue Reading

References

Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Dec 3, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerHans J Hammers
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Apr 22, 2015·The New England Journal of Medicine·Michael A PostowF Stephen Hodi
Apr 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott N GettingerJulie R Brahmer
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 24, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Sep 24, 2015·The New England Journal of Medicine·Matias E Valsecchi
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Feb 11, 2016·Immunotherapy·Bing Xia, Roy S Herbst
Oct 9, 2016·The New England Journal of Medicine·Alexander M M EggermontAlessandro Testori
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Jan 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandra P D'AngeloJedd D Wolchok
Feb 9, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R HuiN A Rizvi
Jun 22, 2017·The New England Journal of Medicine·David P CarboneUNKNOWN CheckMate 026 Investigators
Feb 8, 2018·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Clément GauvainIsabelle Monnet
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators

❮ Previous
Next ❯

Citations

Sep 29, 2020·Future Science OA·Edward B MaldonadoVinay Prasad
Mar 11, 2021·Science Progress·Mohammed Al NuhaitYousef Al Awlah
Jul 2, 2019·Asia-Pacific Journal of Oncology Nursing·Fedricker Diane Barber

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Vivianne Nguyen, Mostaqul Huq
© 2022 Meta ULC. All rights reserved